Deutsche Bank
HRTX icon

Deutsche Bank’s Heron Therapeutics HRTX Stock Holding History

Deutsche Bank’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-520
Closed -$8K – 4683
2021
Q1 		$8K Buy
+520
New +$9.27K ﹤0.01% 4446

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Deutsche Bank's HRTX Position: Q1 2026 in Review

Deutsche Bank held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 93,081 shares worth $74.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3364.

Deutsche Bank first reported a position in HRTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $36.7M in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Deutsche Bank held 93,081 shares of Heron Therapeutics worth $74.5K as of Q1 2026.
  • Deutsche Bank left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #3364 holding.
  • Deutsche Bank first reported a position in Heron Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Deutsche Bank's Heron Therapeutics position peaked at $36.7M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.